Pressure BioSciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events	6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	7) Subsequent Events From July 1, 2023 through August 18, 2023 the Company entered into one (1) new merchant cash loan agreement in the amount of $30,000 and issued one (1) convertible loan with a principal balance of $27,500. The terms of the convertible note were 90 days with an interest rate of 18% and convertible into the Company’s common stock at a fixed rate of $2.50 per share. In this time the Company also issued 440,000 shares of common stock and 25 Series BB preferred stock for professional services, 112 Series BB preferred stock for debt extensions and 466,662 shares of common stock for accrued interest paid-in-kind. The company also converted 32.5 Series BB preferred stock into 325,000 shares common stock.

Subsequent Events

6 Months Ended

Jun. 30, 2023

7) Subsequent Events

From July 1, 2023 through August 18, 2023 the Company entered into one (1) new merchant cash loan agreement in the amount of $30,000 and issued one (1) convertible loan with a principal balance of $27,500. The terms of the convertible note were 90 days with an interest rate of 18% and convertible into the Company’s common stock at a fixed rate of $2.50 per share. In this time the Company also issued 440,000 shares of common stock and 25 Series BB preferred stock for professional services, 112 Series BB preferred stock for debt extensions and 466,662 shares of common stock for accrued interest paid-in-kind. The company also converted 32.5 Series BB preferred stock into 325,000 shares common stock.